NNVC · Nanoviricides, Inc. · Metrics
$1.48
+0.18 (+13.85%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 28, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-K filed Sep 28, 2026
Market Cap
$33.18M
Shares
25.52M
Volume · Oct 20
463.58K
Avg daily vol (3M)
415.75K
NNVC metrics
58 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.48
Market cap
$33.18M
Price action
20 metricsPrice change (1W)
+1.6%
Price change (30D)
-23.1%
Price change (3M)
-25.7%
Price change (6M)
+1.6%
Price change (YTD)
+15.0%
Price change (1Y)
-13.3%
Trailing year
Price change (5Y)
-73.5%
52-week high
$2.03
52-week low
$0.85
Change from 52-week high
-36.0%
Change from 52-week low
+52.9%
Annualized volatility
94.4%
Annualized volatility (3M)
86.1%
Beta
2.2
RSI (14D)
47.5
Price vs SMA 50
-0.3%
Price vs SMA 200
+1.6%
Avg volume (3M)
415,265
Relative volume
0.4
Average dollar volume
$570,355
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
25.52M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.8
reciprocal yield 26.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-24.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$8.31M
Net income (TTM)
−$8.22M
Trailing 12 months
Diluted EPS (TTM)
$-0.41
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+34.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-94.7%
Return on assets
-83.2%
Debt / equity
—
Current ratio
2.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$2.79M
Total assets
$9.87M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$7.70M
Capital expenditures (TTM)
—
R&D (TTM)
$4.71M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
48
13F filer change QoQ
-1
Institutional ownership
9.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
2.4%
Private-fund adviser ownership
2.0%
Active holders' share change QoQ
+0.5%
Holder tenure
7.4
Price vs estimated holder cost
-17.9%
Ownership (registered funds)
1 metricsIndex-fund ownership
4.3%
Short interest
3 metricsShort interest
3.6%
Latest settlement · 1.1 days to cover
Days to cover
1.1d
Short-squeeze score
61 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged